The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens.
Marzia Del Re
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Cecilia Barbara
No relevant relationships to disclose
Tiziana Latiano
No relevant relationships to disclose
Enrico Vasile
No relevant relationships to disclose
Elena Zafarana
No relevant relationships to disclose
Stefano Sergio Cordio
No relevant relationships to disclose
Luisa Toffolatti
No relevant relationships to disclose
Miriam Ricasoli
No relevant relationships to disclose
Angela Prestifilippo
No relevant relationships to disclose
Filippo Venturini
No relevant relationships to disclose
Samantha Di Donato
No relevant relationships to disclose
Federico Grifalchi
No relevant relationships to disclose
Antonio Rinaldi
No relevant relationships to disclose
Alfredo Butera
No relevant relationships to disclose
Evaristo Maiello
No relevant relationships to disclose
Salvatore Siena
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose
Federico Cappuzzo
No relevant relationships to disclose
Romano Danesi
No relevant relationships to disclose